Opendata, web and dolomites

CoALIVE TERMINATED

Coenzyme A – Launch of In Vivo Experiments

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CoALIVE project word cloud

Explore the words cloud of the CoALIVE project. It provides you a very rough idea of what is the project "CoALIVE" about.

ground    expert    treatment    approval    diseases    join    acies    underlying    protection    flies    synthesis    obstacles    contribution    granting    labour    compounds    phosphopantetheine    patent    hence    suffering    prior    therapeutics    breaking    implications    drug    assays    expertise    patients    bio    world    metabolic    diverse    associate    coa    compound    alzheimer    phenotypic    recruitment    rare    untreatable    kinase    chemical    forms    evidenced    team    manipulate    national    disease    successful    demonstrated    affords    hindered    accelerate    designation    discovery    medicines    opportunity    population    analytics    cellular    valuable    therapeutic    commercial    metabolism    completion    pathologies    tircon    core    diabetes    ed    facility    market    class    pkan    neurodegeneration    treating    recruit    innovative    facilities    proof    medicinal    strategy    outstanding    model    pantothenate    coenzyme    orphan    alternative    hire    leaders    levels    laboratory    organism    innovation    agency    reaching    environment    models    despite    fruit   

Project "CoALIVE" data sheet

The following table provides information about the project.

Coordinator
ACIES BIO BIOTEHNOLOSKE RAZISKAVE IN RAZVOJ DOO 

Organization address
address: TEHNOLOSKI PARK 21
city: LJUBLJANA
postcode: 1000
website: www.aciesbio.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovenia [SI]
 Total cost 74˙750 €
 EC max contribution 74˙750 € (100%)
 Programme 1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
 Code Call H2020-INNOSUP-02-2016
 Funding Scheme CSA
 Starting year 2017
 Duration (year-month-day) from 2017-09-29   to  2018-09-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACIES BIO BIOTEHNOLOSKE RAZISKAVE IN RAZVOJ DOO SI (LJUBLJANA) coordinator 74˙750.00

Map

 Project objective

Acies Bio is looking to hire an expert on disease model development – particularly whole organism models in fruit flies – to join our drug discovery team developing 4-phosphopantetheine-related compounds for treating a range of Coenzyme A (CoA) metabolism related pathologies. Acies Bio’s lead compound is able to directly manipulate cellular CoA levels, which addresses the common underlying cause of this class of diseases. High therapeutic potential of this innovative treatment has been demonstrated for pantothenate-kinase-associated neurodegeneration (PKAN) and has resulted in the European Medicines Agency granting our lead compound orphan medicinal product designation. Application of this class of compounds to related diseases forms a core part of our Innovation Strategy, and could have far reaching implications in diverse areas such as numerous rare metabolic diseases, Alzheimer's disease and diabetes. This would not only make treatment available to a wider population of patients, suffering from currently untreatable conditions, but also open new opportunities for Acies Bio. Despite being world leaders in the field of CoA metabolism, as evidenced by our contribution to the TIRCON consortium, prior recruitment of relevant expertise has been hindered by obstacles within the national labour market. Hence, this call affords a valuable opportunity to recruit an Innovation Associate, to evaluate existing models in fruit flies, develop new disease models, implement novel phenotypic assays, and lead a dedicated facility. Acies Bio will provide outstanding coordination and support facilities, state-of-the-art chemical synthesis and analytics laboratory and a research-driven, commercial environment. Successful completion of this crucial step for proof-of-concept in alternative metabolic diseases, will accelerate patent protection and market approval of these ground-breaking therapeutics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COALIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COALIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.2.2.)

ERBSN 4 H2020 (2020)

Eastern Romanian Business Support Network support for innovative SMEs

Read More  

H2020 SGA4 (2020)

EEN Northern Netherlands - H2020 SGA4 - Period 2020/21

Read More  

3D-SE (2019)

Innovative digital, multi-parametric and predictable calculation model for the production of fibre reinforced 3D printed parts for aviation applications according to ISO9100

Read More